Biopharmaceutical aspects of FK-506.
FK is a potent immunosuppressive agent. FK can be analyzed in biologic fluids by EIA. The oral absorption of FK is rapid but variable in dogs. After intramuscular administration, FK is slowly and continuously absorbed. FK is primarily eliminated by metabolism. Less than 1% of the administered dose is excreted in the bile or the urine. After chronic intramuscular administration FK inhibits drug metabolism. Monitoring of FK levels in plasma is essential for the proper interpretation of efficacy and toxicity studies.
D000284:Administration, Oral; D000818:Animals; D002851:Chromatography, High Pressure Liquid; D004285:Dogs; D004353:Drug Evaluation, Preclinical; D007124:Immunoenzyme Techniques; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000032:analysis* / Q000493:pharmacokinetics; D008658:Inactivation, Metabolic / Q000187:drug effects; D007273:Injections, Intramuscular; D008297:Male; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology; D011725:Pyridines / Q000008:administration & dosage / Q000032:analysis / Q000493:pharmacokinetics; D051381:Rats; D011919:Rats, Inbred Strains; D016559:Tacrolimus
D007166:Immunosuppressive Agents; D011725:Pyridines; D016559:Tacrolimus